Ferrone, CristinaCristinaFerroneGoyal, LipikaLipikaGoyalQadan, MotazMotazQadanGervais, DebraDebraGervaisSahani, Dushyant VDushyant VSahaniZhu, Andrew XAndrew XZhuHong, Theodore STheodore SHongBlaszkowsky, Lawrence SLawrence SBlaszkowskyTanabe, Kenneth KKenneth KTanabeVangel, MarkMarkVangelAmorim, Barbara JBarbara JAmorimWo, Jennifer YJennifer YWoMahmood, UmarUmarMahmoodPandharipande, Pari VPari VPandharipandeCatana, CiprianCiprianCatanaDuenas, Virginia PVirginia PDuenasCollazo, Yolanda QYolanda QCollazoCanamaque, Lina GLina GCanamaqueDomachevsky, LiranLiranDomachevskyBernstine, Hanna HHanna HBernstineGroshar, DavidDavidGrosharTIFFANY TING-FANG SHIHLi, YanYanLiHerrmann, KenKenHerrmannUmutlu, LaleLaleUmutluRosen, Bruce RBruce RRosenCatalano, Onofrio AOnofrio ACatalano2021-03-222021-03-22202016197070https://scholars.lib.ntu.edu.tw/handle/123456789/554370Intrahepatic cholangiocarcinoma (ICC) is associated with a poor prognosis with surgical resection offering the best chance for long-term survival and potential cure. However, in up to 36% of patients who undergo surgery, more extensive disease is found at time of operation requiring cancellation of surgery. PET/MR is a novel hybrid technology that might improve local and whole-body staging in ICC patients, potentially influencing clinical management. This study was aimed to investigate the possible management implications of PET/MR, relative to conventional imaging, in patients affected by untreated intrahepatic cholangiocarcinoma.animationCholangiocarcinoma; Clinical management; PET/MR; Staging[SDGs]SDG3antineoplastic agent; fluorodeoxyglucose f 18; gadolinium pentetate meglumine; gadoterate meglumine; fluorodeoxyglucose f 18; radiopharmaceutical agent; adult; advanced cancer; aged; Article; bile duct carcinoma; cancer chemotherapy; cancer radiotherapy; cancer surgery; clinical article; clinical feature; diaphragm; early cancer; female; follow up; human; inferior cava vein; inoperable cancer; laparoscopy; male; McNemar test; nuclear magnetic resonance imaging; peritoneum metastasis; positron emission tomography; positron emission tomography-computed tomography; retrospective study; bile duct cancer; bile duct carcinoma; cancer staging; diagnostic imaging; middle aged; nuclear magnetic resonance imaging; nuclear magnetic resonance spectroscopy; pathology; positron emission tomography; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studiesjournal article10.1007/s00259-019-04558-3317051722-s2.0-85075088300https://api.elsevier.com/content/abstract/scopus_id/85075088300